|
Sign In to gain access to subscriptions and/or personal tools.
|
Topical Review: Baclofen in the Treatment of Cerebral Palsy
A. Leland Albright, MD
Departments of Neurosurgery, Children's Hospital of Pittsburgh and University of Pittsburgh School of Medicine, Pittsburgh, PA
Baclofen, a  -aminobutyric acid agonist, acts at the spinal cord level to impede the release of excitatory neurotransmitters that cause spasticity. Oral baclofen improves cerebral spasticity mildly, but its activity is limited because of its poor lipid solubility. Cerebrospinal fluid baclofen levels after intrathecal administration are many times higher than those achieved after oral administration. Continuous intrathecal baclofen infusion has been used to treat cerebral spasticity in two patient groups: in older ambulatory children with inadequate underlying leg strength, and in patients with severe spasticity in both the upper and lower extremities. Responsiveness to intrathecal baclofen is confirmed by test injections before insertion of a programmable subcutaneous pump. Continuous intrathecal baclofen infusion dosages vary from 27 to 800 µg/day. Continuous intrathecal baclofen infusion reduces spasticity in the upper and lower extremities, and improves upper extremity function and activities of daily living but has no effect on athetosis in the dosages used to treat spasticity. Complications related to the intrathecal catheter occur in approximately 20% of patients, and infection requiring pump removal occurs in approximately 5%. Preliminary studies indicate that continuous intrathecal baclofen infusion alleviates some forms of generalized dystonia associated with cerebral palsy. (J Child Neurol 1996;11:77-83).
Journal of Child Neurology, Vol. 11, No. 2,
77-83 (1996)
DOI: 10.1177/088307389601100202
 CiteULike  Connotea  Del.icio.us  Digg  Reddit  Technorati What's this?
This article has been cited by other articles:
|
|
|
|
 
P. Watson
Modulation of involuntary movements in cerebral palsy with acupuncture
Acupunct Med,
June 1, 2009;
27(2):
76 - 78.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. Kofler, E. Quirbach, R. Schauer, M. Singer, and L. Saltuari
Limitations of Intrathecal Baclofen for Spastic Hemiparesis Following Stroke
Neurorehabil Neural Repair,
January 1, 2009;
23(1):
26 - 31.
[Abstract]
[PDF]
|
|
|
|
|
|
|
A. I. Dai, M. Wasay, and S. Awan
Botulinum Toxin Type A with Oral Baclofen Versus Oral Tizanidine: A Nonrandomized Pilot Comparison in Patients with Cerebral Palsy and Spastic Equinus Foot Deformity
J Child Neurol,
December 1, 2008;
23(12):
1464 - 1466.
[Abstract]
[PDF]
|
|
|
|
|
|
|
L. Lubsch, R. Habersang, M. Haase, and S. Luedtke
Oral Baclofen and Clonidine for Treatment of Spasticity in Children
J Child Neurol,
December 1, 2006;
21(12):
1090 - 1092.
[Abstract]
[PDF]
|
|
|
|
|
|
|
J H Patrick, A P Roberts, and G F Cole
Therapeutic choices in the locomotor management of the child with cerebral palsy{---}more luck than judgement?
Arch. Dis. Child.,
October 1, 2001;
85(4):
275 - 279.
[Full Text]
[PDF]
|
|
|
|
|
|
|
H. S. Singer, J. Wendlandt, M. Krieger, and J. Giuliano
Baclofen treatment in Tourette syndrome: A double-blind, placebo-controlled, crossover trial
Neurology,
March 13, 2001;
56(5):
599 - 604.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
E. M. Goldstein
Spasticity Management: An Overview
J Child Neurol,
January 1, 2001;
16(1):
16 - 23.
[Abstract]
[PDF]
|
|
|
|
|
|
|
A. L. Albright and B. L. Shultz
Plasma Baclofen Levels in Children Receiving Continuous Intrathecal Baclofen Infusion
J Child Neurol,
June 1, 1999;
14(6):
408 - 409.
[Abstract]
[PDF]
|
|
|
|
|
|
|
A. L. Albright
Intrathecal Baclofen in Cerebral Palsy Movement Disorders
J Child Neurol,
November 1, 1996;
11(1_suppl):
S29 - S35.
[Abstract]
[PDF]
|
|
|
|
|
|
|
J. B. Bodensteiner
The Management of Cerebral Palsy: Subjectivity and a Conundrum
J Child Neurol,
March 1, 1996;
11(2):
75 - 76.
[PDF]
|
|
|
|
|
